Akamis Bio is a startup based in the United Kingdom, most recent round Series A, 2 tracked investors.
Based in the United Kingdom, Akamis Bio is a startup founded in 2020. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
Akamis Bio is a clinical-stage oncology company developing Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics to treat solid tumors, primarily focusing on colorectal cancer by using intravenously delivered viral vectors to activate the patient's immune system against tumor cells.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.